9
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Cytotoxicity of antineoplastic agents on rabbit corneal epithelium in vitro

, , &
Pages 79-87 | Published online: 27 Sep 2008

References

  • Vizel M., Oster M. W. Ocular side effects of cancer chemotherapy. Cancer 1982; 49: 1999–2002
  • Doroshow J. H., Locker G. Y., Gaasterland D. E., Hubbard S. P., Young R. C., Myers C. E. Ocular irritation from high-dose methotrexate therapy: Pharmacokinetics of drug in the tear film. Cancer 1981; 48: 2158–2162
  • Griffin J., Garnick M. Eye toxicity of cancer chemotherapy: A review of the literature. Cancer 1981; 48: 1539–1549
  • Christophidis N., Lucas I., Vajda F., Louis W. J. Lacrimation and 5-FU. Ann. Intern. Med. 1978; 89: 574
  • Johnson D. R., Burns R. P. Blepharoconjunctivitis associated with cancer chemotherapy. Transactions, Pacific Coast Otoophthalmology Society Annual Meeting 1965; 46: 43–49
  • Hamersley J., Luce J. K., Florentz T. R., Burkholder M. M., Pepper J. J. Excessive lacrimation from fluorouracil treatment. J.A.M.A. 1973; 225: 147–748
  • Haidak D. J., Hurwitz B. S., Yeung K. Y. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann. Intern. Med. 1978; 88: 657
  • Caravella L. P., Burns J. A., Zangmeister M. Punctal-canalicular stenosis related to system fluorouracil therapy. Arch. Ophthalmol. 1981; 99: 284–286
  • Straus D. J., Mausolf F. A., Ellerby R. A., McCracken J. D. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med. Pediatr. Oncol. 1977; 3: 5–19
  • Grever M. R., Siaw M. F. E., Jacob W. F., Weidhart J. A., Miser J. J., Coleman M. S., Huffer J. J., Balcerzak S. P. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406–417
  • Major P. P., Agarwall R. P., Kufe D. W. Clinical pharmacology of deoxycoformycin. Blood 1981; 58: 91–96
  • Rudnick S. A., Cadman E. C., Capizzi R. L., Skeel R. T., Bertino J. R., McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189–1193
  • Capizzi R. L., Griffin F., Cheng Y. C., Bailey K., Rudnick S. A. High dose ara-C with asparaginase (A'ase) in the treatment of refractory leukemia. Proc. Am. Cancer Res. A.S.C.O. 1979; 27: 148
  • Herzig R. H., Wolff S. N., Lazarus H. M., Philips G. L., Karanes C., Herzig G. P. High dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
  • Hopen G., Mondino B. J., Johnson B. L., Chervenick P. Corneal toxicity with systemic cytarabine. Am. J. Ophthalmol. 1981; 97: 500–504
  • Ritch P. S., Hansen R. M., Heuer D. K. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983; 51: 430–432
  • Lass J. H., Lazarus H. M., Reed M. D., Herzig R. H. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am. J. Ophthalmol. 1982; 94: 617–621
  • Hande K. R., Stein R. S., McDonough D. A., Greco F. A., Wolff S. N. Effects of high-dose cytarabine. Clin. Pharmacol. Ther. 1982; 31: 669–674
  • Castleberry R. P., Crist W. M., Holbrook T., Mullah A., Gaddy D. The cytosine arabinoside (Ara C) syndrome. Med. Pediatr. Oncol. 1981; 9: 257–264
  • Fraunfelder F. T., Meyer S. M. Ocular toxicity of antineoplastic agents. Ophthalmology 1983; 90: 1–3
  • Kaufman H. E., Capella J. A., Maloney E. D., Robbins J. E., Cooper G. M., Uotila M. H. Corneal toxicity of cytosine arabinoside. Arch. Ophthalmol. 1964; 72: 535–540
  • Mallick K. S., Hajek A. S., Parrish R. K. Fluorouracil (5-FU) and cytarabine inhibition of corneal epithelial cell and conjunctival fibroblast proliferation. Arch. Ophthalmol. 1985; 103: 1398–1402
  • Imperia P. S., Lazarus H. M., Botti R. E., Jr., Lass J. H. An in vitro method for measuring ophthalmic preservative cytotoxicity. J. Toxicol.-Cut. Ocular Toxicol. 1986; 5: 309–317
  • Martin B. M., Gimbrone M. A., Unanue E. R., Cotran R. S. Stimulation of nonlymphoid mesenchymal cell proliferation by a macrophage-derived growth factor. J. Immunol. 1981; 726: 1510–1515
  • Capizzi R. L., Yang J. L., Cheng E., Bjornsson T., Sahasrabuaha O., Tan R. S., Cheng Y. C. Alterations of the pharmacokinetics of high-dose Ara C by its metabolite Ara U, in patients with acute leukemia. J. Clin. Oncol. 1983; 7: 763–771
  • Hartnett M., Lazarus H., Murphy B., Reed M., Lass J. Topical corticosteroid versus 2-deoxycytidine therapy of systemic Ara-C induced keratitis. Invest. Ophthal. Mol. Vis. Sci. 1987; 28(Suppl.)309
  • Bleyer W. A. The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 1978; 41: 36–51
  • Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brignatelli L., Brambilla C., DeLena M., Tarcini G., Bajetta E., Musumeci R., Veronesi U. Combination chemotherapy as an adjuvant treatment in inoperable breast cancer, TV. Engl. J. Med. 1976; 294: 405–410
  • Grant W. M. Toxicology of the Eye. Charles C. Thomas, Springfield, Illinois 1974; 1010–1012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.